Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2022 08:00 ET | Source: Immutep Limited

Immutep Quarterly Activities Report

Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and...
July 06, 2022 08:00 ET | Source: Immutep Limited

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
June 27, 2022 08:00 ET | Source: Immutep Limited

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
June 03, 2022 14:18 ET | Source: Immutep Limited

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114)Combination of...
June 02, 2022 08:00 ET | Source: Immutep Limited

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
May 27, 2022 08:00 ET | Source: Immutep Limited

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022Improved...
May 20, 2022 08:00 ET | Source: Immutep Limited

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
May 18, 2022 08:00 ET | Source: Immutep Limited

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
May 04, 2022 08:00 ET | Source: Immutep Limited

Immutep Presents New and Significant Data from the AIPAC Study

Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the...
April 29, 2022 08:00 ET | Source: Immutep Limited

Immutep Quarterly Activities Report

New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmarkConstructive feedback...